OBI Pharma, Inc., was founded in 2002. Its focus is on the ‘Unmet Medical Needs’ in challenging diseases throughout the world, such as Cancer & Infectious Diseases. OBI strives to improve health and the quality of life through innovative and cost-effective therapeutics.
OBI’s core competence is its R&D expertise in developing novel cancer and infectious disease therapies. The company uses its proprietary OPopS™ drug discovery platform to build a ground-breaking pipeline. OBI also works in close collaboration with prestigious research institutes, including Academia Sinica of Taiwan and the Memorial Sloane-Kettering Cancer Center of the US.
The company’s flagship product in development is OBI-822, a first-in-class active immunotherapy for metastatic breast cancer. The on-going Phase 2/3 multinational, randomized controlled trial for metastatic breast cancer (ClinicalTrials.gov Identifier: NCT01516307) was launched in 2011. OBI is also devoted to developing next generation active immunotherapies for difficult to treat cancers, including lung, prostate, pancreatic, stomach, and ovarian. The company is the license holder for DIFICID™ in Taiwan and owns the commercial rights to the product, a novel antibiotic indicated for C. difficile-associated diarrhea.
OBI is listed on Taiwan’s GreTai Securities Market Exchange as an Emerging Company (Stock code: 4174). It has established wholly-owned subsidiaries in the US and China. The company is led by a management team with a track record of success in new drug development and commercialization.
OBI Pharma, Inc.
Address：Ste W1907, 19F, #3, Park St, Nankang Software Park,
Taipei, 11503, TAIWAN